MAPT and Alzheimer disease: Since reduced proteasomal activity and increased tau accumulation has been observed in the brains of AD patients [18], enhancing the activity of the proteasome may offer a potential therapeutic avenue for the treatment of diseases associated with the accumulation of aggregate-prone proteins.